Exchange: NASDAQ·Updated 05:17 AM EDT
AVXL logo

AVXL Anavex Life Sciences Corp

$3.00
$0.11
(3.81%)
Pre-Market
Prev Close $2.89
Reported EarningsAug 25
Mkt Cap$266.04M
Vol13.00

About AVXL

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
38

Bearish Sentiment

How do you feel about AVXL?

Advertisement|Remove ads.